Continuous Delivery of Endogenous Inhibitors from Poly (Lactic-Co-Glycolic Acid) Polymeric Microspheres Inhibits Glioma Tumor Growth

Clinical Cancer Research

Volumn 11, Issue 2, 2005, Pages 768-776

  Benny, Ofra ^a   Duvshani Eshet, Maayan ^a   Cargioli, Theresa ^d   Bello, Lorenzo ^b   Bikfalvi, Andreas ^c   Carroll, Rona S ^d   Machluf, Marcelle ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF MILAN   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPEXIN; MICROSPHERE; POLYGLACTIN; RG 502; THROMBOCYTE FACTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CAPILLARY ENDOTHELIUM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GLIOMA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; UMBILICAL VEIN;

ANIMALS; BIOCOMPATIBLE MATERIALS; BRAIN NEOPLASMS; CATTLE; COAGULANTS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; GLIOBLASTOMA; HEMOPEXIN; HUMANS; IMMUNOENZYME TECHNIQUES; LACTIC ACID; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSPHERES; PEPTIDE FRAGMENTS; PLATELET FACTOR 4; POLYGLYCOLIC ACID; POLYMERS; UMBILICAL VEINS;

EID: 12244298482     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Black PM. Brain tumors. Part 2. N Engl J Med 1991; 324: 1555-64.
2. Satchi-Fainaro R, Pudar M, Davis JW, et al. Targeting angiogenesis with conjugate of HPMA coploymer and TNP-470. Nat Biotechnol 2004; 10: 255–61.
3. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001; 33: 357–69.
4. Jain RK, Schlenger K, Hockel M, Yuan F. Quantitative angiogenesis assays: progress and problems. Nat Med 1997; 3: 1203–8.
5. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–85.
6. Folkman J. Tumor angiogenesis. In: Mendelson J, Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. Philadelphia: W.B. Saunder Co.; 1995. p. 206–33.
7. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23–33.
8. Kisher O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmostic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669–74.
9. Bello L, Carroll RS, Giussani C, Carrabba G, Pluderi M, Lucini V, et al. Suppression of malignant glioma recurrence in a newly developed animal model by fragments of endogenous inhibitors. J Clin Cancer Res 2002; 8: 3539–48.
10. Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001; 19: 35–39.
11. Schmidt NO, Ziu M, Carrabba G, et al. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res 2004; 10: 1255–62.
12. Kim JS, Chang JH, Yu HK, et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 2003; 278: 29000-8.
13. Alonso MJ, Gupta RK, Siber GR, Langer R. Biodegradable microspheres as controlled release tetanus toxoid delivery system. Vaccine 1994; 12: 299-306.
14. Seagal J, Edry E, Keren Z, et al. A fail-safe mechanism for negative selection of isotype-switched B cell precursors is regulated by the Fas/FasL pathway. J Exp Med 2003; 198: 1609-19.
15. Mullerad J, Cohen S, Benharroch D, Apte RN. Local delivery of IL- 1a polymeric microspheres for the immunotherapy of an experimental fibrosarcoma. Cancer Invest 2003; 21: 720-8.
16. Mullerad J, Cohen S, Voronov E, Apte RN. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres. Cytokine 2000; 12: 1683-90.
17. Sanchez A, Gupta RK, Alonso MJ, Siber GR, Langer R. Pulsed controlled-released system for potential use in vaccine delivery. J Pharm Sci 1996; 85: 547-52.
18. Roullin VG, Lemaire L, Venier-Julienne MC, Faisant N, Franconi F, Benoit JP. Release kinetics of 5-fluorouracil-loaded microspheres on an experimental rat glioma. Anticancer Res 2003;23:21–25.
19. Arshady R. Preparation of biodegradable microspheres and microcapsules: polyactideandrelatedpolymers. JControl Release 1991; 17: 1-121.
20. Edlund U, Albertsson A-C. Degradable polymer microspheres for controlled drug delivery. Adv Polym Sci 2002; 157: 67-112.
21. Menei P, Jadaud E, Faisant N, et al. Stereotaxic implantation of 5-fluorouracil-releasing microsphees in malignant glioma. Cancer 2004; 100: 405-10.
22. Bello L, Lucini V, Carrabba G, et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 2001; 61: 8730-6.
23. Jouan V, Canron X, Alemany M, et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 1999;94:984–93.
24. Hagedorn M, Zilberberg L, Lozano RM. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J 2001; 15: 550-552.
25. Neufeld G, Gospodarowicz D. Identification of the fibroblast growth factor receptor in human vascular endothelial cells. J Cell Physiol 1988; 136: 537-42.
26. Moscatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 1987; 131: 123-30.
27. Bello L, Carrabba G, Giussani C, et al. Low dose chemotherapy combined with an anti angiogenic drug reduces human glioma growth in vivo. Cancer Res 2001; 61: 7501-6.
28. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 1995; 345: 1008-12.
29. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997; 41: 44-48.
30. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003; 5: 79-88.
31. Menei P, Daniel V, Montero-Menei C, Brouillard M, Pouplard-Barthelaix A, Benoit JP. Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. Biomaterials 1993; 14: 470-8.
32. Fournier E, Passirani C, Vonarbourg A, et al. Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. Int J Pharm 2003; 268: 31-5.
33. Gohlke U, Gomis-Ruth F, Crabbe T, Murphy G, Docherty AJ, Bode W. The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett 1996; 378: 126-30.
34. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with avh3 integrin. Cell 1996; 85: 683-93.
35. Brooks P, Silletti S, von Schalscha T, Friedlander M, Cheresh D. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
36. Giussani C, Carrabba G, Pluderi M, et al. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. Cancer Res 2003; 63: 2499-505.